Stockreport

Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile [Seeking Alpha]

Unicycive Therapeutics, Inc.  (UNCY) 
PDF OLC targets hyperphosphatemia in CKD dialysis patients, offering competitive advantages like lower pill burden, smaller size, and swallowable tablets. The prior FDA r [Read more]